PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and
gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell
lymphoma.